Abstract
Four series of tetracyclic benzo[b]carbazolone compounds possessing more rotatable bonds and higher molecular flexibility were designed by either inserting a linker within the C8-side chain or by opening the middle ketone ring on the basis of compound 5 (Alectinib, CH5424802). Compound 15b was identified showing nearly identical high potency against both wild-type and the gatekeeper mutant ALK kinase (3.4 vs 3.9 nM). This compound has favorable PK profile with an oral bioavailability of 67.1% in rats. Moreover, compound 15b showed significant growth inhibition against ALK driven cancer cells and KARPAS-299 xenograft model.
Keywords:
ALK inhibitors; Anti-cancer; Anti-resistance; Benzo[b]carbazolones; Non-small-cell lung cancer.
Copyright © 2015 Elsevier Masson SAS. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Administration, Oral
-
Anaplastic Lymphoma Kinase
-
Animals
-
Antineoplastic Agents / administration & dosage*
-
Antineoplastic Agents / chemical synthesis
-
Antineoplastic Agents / chemistry
-
Antineoplastic Agents / pharmacology*
-
Biological Availability
-
Carbazoles / administration & dosage
-
Carbazoles / chemistry
-
Carbazoles / pharmacology*
-
Cell Line, Tumor
-
Cell Proliferation / drug effects
-
Dose-Response Relationship, Drug
-
Drug Design*
-
Drug Screening Assays, Antitumor
-
Female
-
Humans
-
Mice
-
Mice, SCID
-
Molecular Structure
-
Neoplasms, Experimental / drug therapy
-
Neoplasms, Experimental / pathology
-
Protein Kinase Inhibitors / administration & dosage*
-
Protein Kinase Inhibitors / chemical synthesis
-
Protein Kinase Inhibitors / chemistry
-
Protein Kinase Inhibitors / pharmacology*
-
Rats
-
Receptor Protein-Tyrosine Kinases / antagonists & inhibitors*
-
Receptor Protein-Tyrosine Kinases / metabolism
-
Structure-Activity Relationship
Substances
-
Antineoplastic Agents
-
Carbazoles
-
Protein Kinase Inhibitors
-
ALK protein, human
-
Alk protein, mouse
-
Alk protein, rat
-
Anaplastic Lymphoma Kinase
-
Receptor Protein-Tyrosine Kinases